- Home
- FAX vs OMER Comparison
FAX vs OMER Comparison
Compare FAX & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FAX | OMER |
|---|---|---|
| Founded | 1986 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 599.0M | 844.6M |
| IPO Year | N/A | 2008 |
Fundamental Metrics
Financial Performance| Metric | FAX | OMER |
|---|---|---|
| Price | $14.65 | $17.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.50 |
| AVG Volume (30 Days) | 127.2K | ★ 2.2M |
| Earning Date | 01-01-0001 | 05-14-2026 |
| Dividend Yield | ★ 12.09% | N/A |
| EPS Growth | N/A | ★ 98.15 |
| EPS | N/A | ★ 0.77 |
| Revenue | N/A | ★ $29,868,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $233.22 |
| P/E Ratio | ★ N/A | $22.55 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $14.13 | $3.94 |
| 52 Week High | $16.90 | $18.14 |
Technical Indicators
Market Signals| Indicator | FAX | OMER |
|---|---|---|
| Relative Strength Index (RSI) | 54.96 | 81.34 |
| Support Level | $14.43 | $9.40 |
| Resistance Level | $14.67 | $17.65 |
| Average True Range (ATR) | 0.14 | 0.72 |
| MACD | 0.02 | 0.52 |
| Stochastic Oscillator | 89.29 | 85.97 |
Price Performance
Historical ComparisonAbout FAX abrdn Asia-Pacific Income Fund Inc.
Aberdeen Asia-pacific Income Fund Inc is a United States-based closed-end, non-diversified management investment company. Its principal investment objective is to seek current income along with capital appreciation. The fund invests in Asian debt securities, Australian debt securities, European debt securities and others.
About OMER Omeros Corporation
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.